Cytek BioSciences, Inc. (CTKB): Price and Financial Metrics
CTKB Price/Volume Stats
|Current price||$7.83||52-week high||$16.05|
|Prev. close||$8.07||52-week low||$6.45|
|Day high||$8.04||Avg. volume||1,091,496|
|50-day MA||$9.20||Dividend yield||N/A|
|200-day MA||$11.64||Market Cap||1.06B|
CTKB Stock Price Chart Interactive Chart >
CTKB POWR Grades
- Value is the dimension where CTKB ranks best; there it ranks ahead of 60.11% of US stocks.
- The strongest trend for CTKB is in Stability, which has been heading down over the past 179 days.
- CTKB's current lowest rank is in the Momentum metric (where it is better than 5.91% of US stocks).
CTKB Stock Summary
- With a one year PEG ratio of 344.79, CYTEK BIOSCIENCES INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 92.96% of US stocks.
- CYTEK BIOSCIENCES INC's stock had its IPO on July 23, 2021, making it an older stock than merely 4.35% of US equities in our set.
- Over the past twelve months, CTKB has reported earnings growth of -141.01%, putting it ahead of merely 11.16% of US stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to CYTEK BIOSCIENCES INC are MRCY, CDNA, SONO, NCNO, and RDWR.
- To check out CYTEK BIOSCIENCES INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001831915.
CTKB Valuation Summary
- CTKB's price/sales ratio is 6.4; this is 190.91% higher than that of the median Healthcare stock.
- Over the past 22 months, CTKB's EV/EBIT ratio has gone down 664.8.
Below are key valuation metrics over time for CTKB.
CTKB Price Target
For more insight on analysts targets of CTKB, see our CTKB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
|Average Price Target||$27.00||Average Broker Recommendation||1.67 (Moderate Buy)|
Cytek BioSciences, Inc. (CTKB) Company Bio
Cytek Biosciences, Inc. engages in the manufacture and sale of cell analysis solutions for clinical and biomedical research in the fields of drug discovery, genomics, immuno-oncology, immuno-profiling, infectious diseases, inflammatory diseases, and multi-site standardization applications. Its instruments include the Aurora and Northern Lights systems, which are flow cytometers to deliver cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. The company also offers cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments. Its customers include pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. The company distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. Cytek Biosciences, Inc. was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. The company was incorporated in 2014 and is headquartered in Fremont, California.
Most Popular Stories View All
CTKB Latest News Stream
|Loading, please wait...|
CTKB Latest Social Stream
View Full CTKB Social Stream
Latest CTKB News From Around the Web
Below are the latest news stories about CYTEK BIOSCIENCES INC that investors may wish to consider to help them evaluate CTKB as an investment opportunity.
Cytek Biosciences to Participate in the 44th Annual Goldman Sachs Healthcare Conference
FREMONT, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming 44th Annual Goldman Sachs Healthcare Conference in Dana Point, CA. Cytek management is scheduled to participate in a fireside chat on Wednesday, June 14th at 3:20 p.m. Pacific Time / 6:20 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investor
Cytek Biosciences Announces $50 Million Stock Repurchase Program
FREMONT, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that its Board of Directors has approved the repurchase of up to an aggregate of $50 million of its common stock, subject to compliance with applicable law. The Company’s common stock is listed on The Nasdaq Global Select Market under the symbol “CTKB”. The repurchase program will continue until the end of the fiscal year unless extended or shortene
Cytek® Biosciences Marks Shipment of Its 100th Cell Sorter as the Company Continues to Lead Cell Analysis Forward
Cytek Aurora CS Cytek® has shipped its 100th Cytek Aurora CS system. Built on the same Full Spectrum Profiling™ technology comprising Cytek’s Aurora cell analysis system, the Aurora CS delivers high-sensitivity capabilities at the single-cell level to resolve and sort even the most challenging cell populations. FREMONT, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, announced today that it has shipped its 100th Cytek Au
Cytek Biosciences, Inc. (CTKB) Q1 2023 Earnings Call Transcript
Cytek Biosciences, Inc. (CTKB)
Q1 2023 Earnings Conference Call
May 9, 2023 4:30 PM ET
Paul Goodson - Head Investor Relations
Wenbin Jiang - Chief Executive Officer
Patrik Jeanmonod - Chief Financial Officer
Conference Call Participants
David Westenberg - Piper Sandler
Stephanie Yan - TD Cowen
Good afternoon, and thank you for standing by. Welcome to the Cytek Biosciences First Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions]. As a reminder, today's con...
Why Shares of Cytek Biosciences Dropped This Week
Shares of Cytek Biosciences (NASDAQ: CTKB) were down 36.3% for the week as of Friday afternoon, according to data provided by S&P Global Market Intelligence. Cytek, which joined the S&P 600 Index in April, saw increased losses in Q1. Another reason why investors didn't react favorably to the earnings report was the company revised revenue guidance downward.
CTKB Price Returns
Loading social stream, please wait...